Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Denis

Showing results (181-190 of 310) with videos related to

Pageof 31
Sort By:
Molecular and Cellular Biology|April 1, 1992
ADR1c mutations enhance the ability of ADR1 to activate transcription by a mechanism that is independent of effects on cyclic AMP-dependent protein kinase phosphorylation of Ser-230C L Denis, S C Fontaine, D Chase, et al.
Cell|February 10, 1989
Cyclic AMP-dependent protein kinase phosphorylates and inactivates the yeast transcriptional activator ADR1J R Cherry, T R Johnson, C Dollard, et al.
International Journal of Pharmaceutics|May 6, 2014
Stability study of full-length antibody (anti-TNF alpha) loaded PLGA microspheresS Marquette, C Peerboom, A Yates, et al.
Proteins|November 18, 2021
The non-prion SUP35 preexists in large chaperone-containing molecular complexesShiwha Park, Xin Wang, Wen Xi, et al.
Cancer|July 1, 1992
Alternatives to surgery for benign prostatic hyperplasiaL Denis, H Lepor, J Dowd, et al.
Scandinavian Journal of Urology and Nephrology. Supplementum|January 6, 2001
Prevention of prostate cancerC C Schulman, A R Zlotta, L Denis, et al.
Journal of Molecular Biology|December 6, 2001
Purification and characterization of the 1.0 MDa CCR4-NOT complex identifies two novel components of the complexJ Chen, J Rappsilber, Y C Chiang, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
Current status of intravesical chemotherapy trials in the EORTC Urological Group. An overviewL Denis, C Bouffioux, K H Kurth, et al.
European Urology|February 21, 1998
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study GroupC J Tyrrell, L Denis, D Newling, et al.
Annales De Dermatologie Et De Venereologie|May 7, 2008
[Patterns of skin diseases in the elderly]J-L Perrot, B Labeille, L Denis Thely, et al.
Pageof 31

Showing results (181-190 of 310) with videos related to

Sort By:
Pageof 31
Molecular and Cellular Biology|April 1, 1992
ADR1c mutations enhance the ability of ADR1 to activate transcription by a mechanism that is independent of effects on cyclic AMP-dependent protein kinase phosphorylation of Ser-230C L Denis, S C Fontaine, D Chase, et al.
Cell|February 10, 1989
Cyclic AMP-dependent protein kinase phosphorylates and inactivates the yeast transcriptional activator ADR1J R Cherry, T R Johnson, C Dollard, et al.
International Journal of Pharmaceutics|May 6, 2014
Stability study of full-length antibody (anti-TNF alpha) loaded PLGA microspheresS Marquette, C Peerboom, A Yates, et al.
Proteins|November 18, 2021
The non-prion SUP35 preexists in large chaperone-containing molecular complexesShiwha Park, Xin Wang, Wen Xi, et al.
Cancer|July 1, 1992
Alternatives to surgery for benign prostatic hyperplasiaL Denis, H Lepor, J Dowd, et al.
Scandinavian Journal of Urology and Nephrology. Supplementum|January 6, 2001
Prevention of prostate cancerC C Schulman, A R Zlotta, L Denis, et al.
Journal of Molecular Biology|December 6, 2001
Purification and characterization of the 1.0 MDa CCR4-NOT complex identifies two novel components of the complexJ Chen, J Rappsilber, Y C Chiang, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
Current status of intravesical chemotherapy trials in the EORTC Urological Group. An overviewL Denis, C Bouffioux, K H Kurth, et al.
European Urology|February 21, 1998
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study GroupC J Tyrrell, L Denis, D Newling, et al.
Annales De Dermatologie Et De Venereologie|May 7, 2008
[Patterns of skin diseases in the elderly]J-L Perrot, B Labeille, L Denis Thely, et al.
Pageof 31